3-way replicate vs. 4-way [GxP / QC / QA]

posted by drmuneesh – 2009-08-17 07:46 (6147 d 10:21 ago) – Posting: # 4049
Views: 10,786

Dear HS

Thank you for the reply. We are planning 4-period replicate design to reduce the number of subjects also. Highly variable drug like risedronate having intrasubject variability of 50-80% would require too many subjects in case of 3-period design. 3-period design may be ok for drugs having intrasubject variability of 30-50%.

Please suggest if I am wrong.

Regards

Dr Muneesh Garg

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
129 visitors (0 registered, 129 guests [including 14 identified bots]).
Forum time: 18:07 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5